Calcium bis(O-acetylsalicylate) | 69-46-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Calcium bis(O-acetylsalicylate)
• 英文别名: calcium;2-acetyloxybenzoate
• CAS: 69-46-5
• 化学式: C18H14CaO8
• 分子量: 398.4
• InChiKey: KRALOLGXHLZTCW-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -0.43
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  133
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Calcium bis(O-acetylsalicylate) 、 钠 、 Potassium benzoate 生成 阿司匹林
  参考文献：
  名称：

  Decreasing the toxicity of an ibuprofen salt

  摘要：

  伊布普洛芬盐的毒性降低了。

  公开号：

  US04873231A1
• 作为产物：
  描述：

  阿司匹林 、 calcium carbonate 在 水 作用下， 以 水 为溶剂， 反应 2.0h， 生成 Calcium bis(O-acetylsalicylate)
  参考文献：
  名称：

  Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or

  摘要：

  由纳布啡和乙酰水杨酸、衍生物或盐基本组成的混合物，具有意外增强的镇痛活性。

  公开号：

  US04282215A1

文献信息

• [EN] ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS<br/>[FR] ANTI-INFECTIEUX A BASE D'ISOTHIAZOLOQUINOLONES ET DE SELS CORRESPONDANTS
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2005019228A1

  公开（公告）日：2005-03-03

  The invention provides compounds and salts of Formula (I) and Formula (II): which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula (I) and Formula (II). The variables A1, R2, R3, R5, R6, R7, A8 and R9 are defined herein. Certain compounds of Formula (I) and Formula (II) disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula (I) or Formula (II) and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula (I) or Formula (II) as the only active agent or may contain a combination of a compound of Formula (I) or Formula (II) and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

  本发明提供了具有抗菌活性的公式(I)和公式(II)的化合物及盐类：本发明还提供了用于制造公式(I)和公式(II)化合物的新的合成中间体。变量A1、R2、R3、R5、R6、R7、A8和R9在此文中定义。本文披露的某些公式(I)和公式(II)化合物是细菌DNA合成和细菌复制的强效和选择性抑制剂。本发明还提供了含有一种或多种公式(I)或公式(II)化合物以及一种或多种载体、辅料或稀释剂的抗菌组合物，包括药物组合物。这样的组合物可以只含有公式(I)或公式(II)的化合物作为唯一的活性成分，也可以含有公式(I)或公式(II)的化合物与一种或多种其他活性成分的组合。本发明还提供了用于治疗动物微生物感染的方法。
• Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
  申请人：——

  公开号：US20020182185A1

  公开（公告）日：2002-12-05

  Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.

  描述了减少或预防个体眼部移植排斥的方法，包括：a) 执行眼部移植手术；和b) 植入眼部一个生物可降解药物输送系统，包括免疫抑制剂和生物可降解聚合物。
• Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
  申请人：Vitreo-Retinal Technologies, Inc.

  公开号：US20040043082A1

  公开（公告）日：2004-03-04

  Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, guanidinium chloride, guanidinium salts, thymidine, thymitadine, uradine, uracil, cysteine), reduced thioctic acid, uric acid, calcium acetyl salicylate, ammonium sulfate, isopropyl alcohol, ethanol, polyethylene glycol, polypropylene glycol or other compound capable of causing nonenzymatic dissolution of the corneal protoeglycans or f) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.

  用于治疗眼部疾病和/或引起角膜蛋白聚糖溶解和角膜基质有序愈合的方法和制剂，软化角膜以进行非手术屈光矫正，去除角膜雾化和混浊，抑制成纤维细胞并预防角膜纤维化和瘢痕形成，治疗翼状胬肉和治疗角膜新生血管化以及虹膜新生血管化。含有a）尿素，b）尿素衍生物（例如，羟基脲，硫脲），c）抗代谢物，e）尿素，尿素衍生物，非酶蛋白，核苷，核苷酸及其衍生物（例如，腺嘌呤，腺苷，胞嘧啶，胞苷，鸟嘌呤，鸟苷，胍，胍盐，胍盐酸盐，胸苷，胸苷，尿苷，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿嘧啶，尿